
BIOGY
Healthcare · Drug Manufacturers - Specialty & Generic · $990.4M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2026
EPS trend, 90 days to now
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Oct 20, 2025 | Before the open | — | 0.07 | — |
| Jul 18, 2025 | Before the open | — | 0.09 | — |
| May 5, 2025 | Before the open | — | 0.07 | — |
| Feb 12, 2025 | Before the open | — | 0.08 | — |
| Oct 22, 2024 | Before the open | — | 0.03 | — |
| Jul 23, 2024 | Before the open | — | 0.10 | — |
| May 7, 2024 | Before the open | — | 0.12 | — |
| Feb 7, 2024 | Before the open | — | 0.06 | — |
| Sep 30, 2021 | Time not confirmed | — | 0.30 | — |
| Jun 30, 2021 | Time not confirmed | — | 0.32 | — |
| Mar 31, 2021 | Time not confirmed | — | 0.29 | — |
| Dec 31, 2020 | Time not confirmed | — | 0.25 | — |
| Sep 30, 2020 | Time not confirmed | — | 0.13 | — |
| Jun 30, 2020 |
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that…
| Time not confirmed |
| — |
| 0.49 |
| — |
| Mar 31, 2020 | Time not confirmed | — | 0.24 | — |
| Dec 31, 2019 | Time not confirmed | — | 0.32 | — |
| Sep 30, 2019 | Time not confirmed | — | 0.22 | — |
| Jun 30, 2019 | Time not confirmed | — | 0.38 | — |
| Mar 31, 2019 | Time not confirmed | — | 0.22 | — |
| Dec 31, 2018 | Time not confirmed | — | 0.37 | — |
| Sep 30, 2018 | Time not confirmed | — | 0.33 | — |
| Jun 30, 2018 | Time not confirmed | — | 0.40 | — |
| Mar 31, 2018 | Time not confirmed | — | 0.30 | — |